[Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
National Committee for Technology Incorporation (Conitec)
Record ID 32018001062
Portuguese
Original Title:
Exclusão da rifampicina para quimioprofilaxia de contatos de pacientes com hanseníase
Authors' results and conclusions:
The Conitec’s members present at the 87th Ordinary Meeting, on June 3rd, 2020, unanimously decided to recommend the exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease, in the scope of SUS. The Deliberation Record No. 517/2020 was signed.
Details
Project Status:
Completed
URL for project:
http://conitec.gov.br/images/Consultas/Relatorios/EN2020/20201119_Report525_ExclusionRifampicin_Chemoprophylaxis.pdf
Year Published:
2020
URL for published report:
http://conitec.gov.br/images/Relatorios/2020/Relatorio_Rifampicina_Quimioprofilaxia_Hansenase_525_2020_FINAL.pdf
URL for additional information:
http://conitec.gov.br/recomendation-reports
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Brazil
MeSH Terms
- Leprosy
- Chemoprevention
- Communicable Disease Control
- Leprostatic Agents
- Rifampin
- Anti-Bacterial Agents
Keywords
- rifampicin
- chemoprophylaxis
- Hansen´s disease
Contact
Organisation Name:
National Committee for Technology Incorporation (CONITEC)
Contact Address:
Esplanada dos Ministérios, Bl. G, Ed. Sede, 8º andar, CEP: 70058-900
Contact Name:
Clarice Moreira Portugal
Contact Email:
clarice.portugal@saude.gov.br
Copyright:
2021 Conitec
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.